Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Coates

Showing results (221-230 of 240) with videos related to

Pageof 24
Sort By:
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
The American Journal of Tropical Medicine and Hygiene|February 10, 2026
Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D VaccineMatheus O de Souza, Danielle R D Saunders, Andrew Miller, et al.
The Journal of Clinical Investigation|July 6, 2026
Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adultsTuan M Tran, Zonghui Hu, Kassoum Kayentao, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 25, 2021
Advancing Antiracism in Community-Based Research Practices in Early Childhood and Family Mental HealthAmbrose Lane, Arrealia Gavins, Ar'Reon Watson, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
Pageof 24

Showing results (221-230 of 240) with videos related to

Sort By:
Pageof 24
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
The American Journal of Tropical Medicine and Hygiene|February 10, 2026
Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D VaccineMatheus O de Souza, Danielle R D Saunders, Andrew Miller, et al.
The Journal of Clinical Investigation|July 6, 2026
Pharmacokinetics and pharmacodynamics of a long-acting monoclonal antibody against malaria in African adultsTuan M Tran, Zonghui Hu, Kassoum Kayentao, et al.
JAMA|April 15, 2020
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical TrialGrace L Chen, Emily E Coates, Sarah H Plummer, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 25, 2021
Advancing Antiracism in Community-Based Research Practices in Early Childhood and Family Mental HealthAmbrose Lane, Arrealia Gavins, Ar'Reon Watson, et al.
Science Translational Medicine|December 25, 2015
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infectionRebecca M Lynch, Eli Boritz, Emily E Coates, et al.
The New England Journal of Medicine|August 11, 2021
A Monoclonal Antibody for Malaria PreventionMartin R Gaudinski, Nina M Berkowitz, Azza H Idris, et al.
NPJ Vaccines|March 30, 2024
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trialsMyra Happe, Amelia R Hofstetter, Jing Wang, et al.
The Lancet. Infectious Diseases|January 28, 2023
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trialKirsten E Lyke, Andrea A Berry, Kaitlin Mason, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
Pageof 24